JPRN-jRCT2051230002进行中（未招募）3 期
A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study
Tanaka Yoshiyuki0 个研究点目标入组 1,300 人开始时间: 2023年4月7日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •'- Is currently receiving doravirine/islatravir (DOR/ISL) adult fixed dose combination (FDC) tablet in Merck Sharp & Dohme (MSD)-sponsored clinical studies (MK-8591A-017, -018, -020, and -033 [except for heavily treatment-experienced (HTE) participants]).
排除标准
- •'- Has confirmed HIV-1 RNA >=200 copies/mL in MSD DOR/ISL (100 mg/0.75 mg) MK-8591A-017 /-018 /-020, or at screening for participants entering from DOR/ISL (100 mg/0.75 mg) MK-8591A-033.
- •- Has confirmatory laboratory findings for cluster of differentiation 4+ (CD4+) T-cell counts or lymphocyte counts in the prior DOR/ISL study that meet criteria for discontinuation of DOR/ISL.
- •- Is a HTE participant receiving treatment in MK-8591A-019 or -033.
研究者
相似试验
进行中（未招募）
1 期
A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravirHIV-1 infectionMedDRA version: 20.1Level: LLTClassification code: 10068341Term: HIV-1 infection Class: 10021881CTIS2022-502126-40-00Merck Sharp & Dohme LLC1,312
进行中（未招募）
3 期
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)HIV InfectionNCT05766501Merck Sharp & Dohme LLC641
已完成
3 期
Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia SyndromeSevere Fever with Thrombocytopenia Syndrome (SFTS)JPRN-jRCT2080223816FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)30
招募中
3 期
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 InfectionNCT06203132ANRS, Emerging Infectious Diseases610
已完成
3 期
DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIVHIV-1-infectionNCT04433780Professor Francois Venter133